Boardroom Alpha
Start trial
10-Q primary document
DTIL · Quarterly Report (Form 10-Q) · Filed August 6, 2026

Precision Biosciences Inc — 10-Q exhibit

dtil-20260630xex103xamendm.htm
Precision Biosciences Inc on Boardroom Alpha
Document


Exhibit 10.3
PRECISION BIOSCIENCES, INC. AMENDMENT TO EXTEND CONSULTING AGREEMENT
This amendment (this “Amendment”), dated and effective as of June 29, 2026 (the “Amendment Effective Date”), is entered into by and between Dr. Stanley R. Frankel, MD (the “Independent Contractor”) and Precision BioSciences, Inc. (“Company”).
WHEREAS, the Independent Contractor and Company have entered into a Consulting Agreement dated June 23, 2025 (the “Agreement”); and
WHEREAS, the parties wish to amend the Agreement to extend its term, pursuant to Section 11(A) and Section 21 of the Agreement and as set forth herein.
NOW, THEREFORE, the parties hereto agree as follows:
1.DEFINITIONS. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Agreement.
2.AMENDMENT TO AGREEMENT TERM. The reference in the first sentence of Section 11(A) to “June 30, 2026” is hereby deleted and replaced with “August 31, 2026”. For clarification, the parties agree that the Agreement will be extended for an additional period, effective upon the expiration of the current Term as set forth in Section 11(A) of the Agreement and continuing through August 31, 2026.
3.CONTINUING EFFECT OF AGREEMENT. Except as expressly provided in this Amendment, all terms of the Agreement shall remain unchanged and in full force and effect. After the Amendment Effective Date, every reference in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment.
IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by duly authorized representatives to be binding and effective as of the Amendment Effective Date.
Stanley R. Frankel, M.D.    Precision BioSciences, Inc.

Sign: /s/ Stanley Frankel        Sign: /s/ Cindy Atwell
Name: Stanley R. Frankel        Name: Cindy Atwell    
Date: June 29, 2026    Title: CDBO

    Date: June 29, 2026    




Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer